The Barre-Montpelier Times Argus

Handa Oncology Receives FDA Final Approval for OMCAZIO(TM) (cabozantinib) Capsules

OMCAZIO approved for administration without regard to food, removing strict fasting requirements for cabozantinib patients ...
RTTNews

Show Me The Money: Filspari Powers Travere Therapeutics' Growth

Travere Therapeutics was first featured on our site on August 14, 2024, when the stock was trading at $8.91. At the time, our ...

Handa Pharma, Inc.: Handa Oncology Receives FDA Final Approval for OMCAZIO Capsules

OMCAZIO approved for administration without regard to food, removing strict fasting requirements for cabozantinib patients SAN JOSE, CA AND TAIPEI, TW / ACCESS Newswire / September 11, 2026 / Handa Ph ...

Eloxx Pharmaceuticals Announces First Patients Dosed in Phase 2b EXACT Study of Exaluren in Nonsense Mutation Alport Syndrome

Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), a clinical-stage biopharmaceutical company developing exaluren for the treatment ...

Eloxx Pharmaceuticals, Inc.: Eloxx Pharmaceuticals Announces First Patients Dosed in Phase 2b EXACT Study of Exaluren in Nonsense Mutation Alport Syndrome

First two patients dosed in the EXACT study Topline data from the initial 16-week placebo-controlled portion of the study expected mid-2027; final readout expected ...